NCT04990037View on ClinicalTrials.gov

A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 19, 2021

Primary Completion Date

May 30, 2023

Study Completion Date

June 15, 2023

Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

CAN04

Administered intravenously

DRUG

FOLFIRINOX

Administered intravenously

Trial Locations (9)

28007

Hospital General Universitario Gregorio Maranon, Madrid

28040

START MADRID_Hospital Universitario Fundacion Jimenez Diaz, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

33000

EDOG - Institut Bergonie - PPDS, Bordeaux

44100

EDOG Institut de Cancerologie de l'Ouest - PPDS, Nantes

44805

Institut de Cancerologie de l'Ouest, Saint-Herblain

Unknown

EDOG - Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer - PPDS, Rennes

08035

Instituto de Investigacion Oncologica Vall d'Hebron (VHIO) - EPON, Barcelona

08908

ICO l'Hospitalet - Hospital Duran i Reynals, Barcelona

Sponsors

Lead Sponsor

Cantargia AB
All Listed Sponsors
lead

Cantargia AB

INDUSTRY